NCT04739670
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: PD-L1
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 100 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have received prior chemotherapy or targeted systemic therapy; Patients with prior treatment of CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody (e.g. Tecentriq/atezolizumab, Keytruda/pembrolizumab); Patients with symptomatic, untreated, or actively progressing central nervous system (CNS) metastases; Patients with a history or presence of leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04739670